サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：放射線毒性 (放射線宿酔・急性放射線症候群) 治療の世界市場 (2023～2031年)：成長・将来の展望・競合分析
市場調査レポート
商品コード
1248131

放射線毒性 (放射線宿酔・急性放射線症候群) 治療の世界市場 (2023～2031年)：成長・将来の展望・競合分析

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
放射線毒性 (放射線宿酔・急性放射線症候群) 治療の世界市場 (2023～2031年)：成長・将来の展望・競合分析
出版日: 2023年01月23日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線治療や核医学を用いたさまざまな疾患の診断・治療の増加に伴い、放射線毒性の発生率は増加傾向にあり、放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場全体の成長を牽引しています。癌の有病率の増加は、放射線毒性のリスクを増大させています。

地域別では、北米が2022年に38%のシェアを占め、次いで欧州が続いています。この優位性は、利用可能な治療法に関する認識が高まっていることに起因しています。また、アジア太平洋は、医療インフラの整備、医療に対する意識の高まり、癌罹患率の増加などから、潜在的な市場として期待されています。

当レポートでは、世界の放射線毒性 (放射線宿酔・急性放射線症候群) 治療の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場：競合分析

  • 主要ベンダーの市場ポジショニング
  • ベンダーの採用戦略
  • 主要な業界戦略
  • ティア分析

第4章 放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場：マクロ分析・市場力学

  • 市場規模の予測
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析

第5章 放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場：治療別

  • 市場概要
  • 成長・収益分析
  • 市場の分類
    • 抗生物質
    • 血液製剤
    • コロニー刺激因子
    • 骨髄移植
    • 幹細胞移植
    • 血液/血小板輸血
    • パイプライン製品

第6章 北米の放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場

第7章 英国およびEUの放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場

第8章 アジア太平洋の放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場

第9章 ラテンアメリカの放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場

第10章 中東およびアフリカの放射線毒性 (放射線宿酔・急性放射線症候群) 治療市場

第11章 企業プロファイル

  • Aeolus Pharmaceuticals
  • Cantex Pharmaceuticals, Inc.
  • Cleveland BioLabs, Inc.
  • Gamida Cell Ltd.
  • Nanotherapeutics, Inc.
  • NeoStem, Inc.
  • Onconova Therapeutics, Inc.
  • Osiris Therapeutics, Inc.
  • Tonix Pharmaceuticals Holding Corp
  • その他
図表

List of Tables

  • TABLE 1 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 2 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 3 North America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 4 North America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 5 U.S. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 6 U.S. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 7 Canada Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 8 Canada Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 13 UK Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 14 UK Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 15 Germany Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 16 Germany Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 17 Spain Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 18 Spain Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 19 Italy Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 20 Italy Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 21 France Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 22 France Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 25 Asia Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 26 Asia Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 27 China Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 28 China Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 29 Japan Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 30 Japan Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 31 India Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 32 India Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 33 Australia Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 34 Australia Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 35 South Korea Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 36 South Korea Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 37 Latin America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 38 Latin America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 39 Brazil Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 40 Brazil Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 41 Mexico Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 42 Mexico Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 47 GCC Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 48 GCC Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 49 Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 50 Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Treatment, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market By Pipeline products, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: Quality Assurance
  • FIG. 5 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, By Treatment, 2022
  • FIG. 6 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, By Geography, 2022
  • FIG. 7 Market Geographical Opportunity Matrix - Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, 2022
  • FIG. 8 Market Positioning of Key Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market Players, 2022
  • FIG. 9 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 10 Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, By Treatment, 2022 Vs 2031, %
  • FIG. 11 U.S. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 12 Canada Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 13 Rest of North America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 14 UK Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 15 Germany Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 16 Spain Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 17 Italy Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 18 France Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of Europe Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 20 China Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 21 Japan Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 22 India Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 23 Australia Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 24 South Korea Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Asia Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 26 Brazil Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 27 Mexico Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 28 Rest of Latin America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 29 GCC Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 30 Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Middle East and Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market (US$ Million), 2021 - 2031
目次
Product Code: 138063-01-23

The incidence of radiation toxicity is on a rise with increase in treatment and diagnosis of various diseases using radiation therapy and nuclear medicine, thus driving the overall market growth. Cancer treatment predominantly utilizes radiation therapy to treat tumours and cancerous cells. Growing prevalence of cancer thus increases the rate of radiation therapy indicating growing risk of radiation toxicity. The American Cancer Society projected 1,735,350 new cancer cases to occur in US in the year 2018 and further estimated 609,640 deaths to occur in the similar year. Based on various research studies, around 60% patients undergo radiation therapy of which 5-10% experience radiation toxicity. However, the high cost of radiation therapy would lead to lesser patients opting for it particularly in low and middle-income regions. This factor could reduce the rate of radiation toxicities thus restraining the market growth.

The treatment options for radiation toxicity comprise bone marrow transplant, blood/ platelet transfusion (used to treat anaemia conditions), and antibiotics (prescribed to diminish the threats of various infections). Aeolus pharmaceuticals is currently developing (Phase I) a molecule named AEOL-10150 for the treatment of acute radiation syndrome.

Radiation toxicity can occur due to either intentional exposure to radiations or accidental exposure such as nuclear power plant accidents. Providing first aid to radiation victims may also increase the risk of exposure of radiation to the rescue personnel. The rising number of respective patients has attracted many pharmaceutical industries to invest in this market and carry out various research activities in development of suitable therapies.

North America predominates the global radiation toxicity treatment market with market share of 38% in 2022, which is followed by Europe. The dominance is attributed to the growing awareness on available treatment options. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness on healthcare and growing cancer prevalence.

The Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market is segmented as follows:

By Treatment

  • Antibiotics
  • Blood products
  • Colony stimulating factors
  • Bone marrow transplant
  • Stem cell transplant
  • Blood/platelet transfusions
  • Pipeline products
  • Tempol ( Phase II)
  • AEOL-10150 (Phase I)

By Geography

  • North America
    • U.S
    • Canada
  • Europe
    • U.K
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Rest of Middle East and Africa

The key industrial players enjoying supremacy in this market are Aeolus Pharmaceuticals, Cantex Pharmaceuticals, Inc., Cleveland BioLabs, Inc., Gamida Cell Ltd., Nanotherapeutics, Inc., NeoStem, Inc., Onconova Therapeutics, Inc., Osiris Therapeutics, Inc., Tonix Pharmaceuticals Holding Corp And Others.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market?
  • Which is the largest regional market for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market
  • 2.2. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, By Treatment, 2022 (US$ Million)
  • 2.3. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, By Geography, 2022 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2022

3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market Vendors
  • 3.2. Strategies Adopted by Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Antibiotics
    • 5.3.2. Blood products
    • 5.3.3. Colony stimulating factors
    • 5.3.4. Bone marrow transplant
    • 5.3.5. Stem cell transplant
    • 5.3.6. Blood/platelet transfusions
    • 5.3.7. Pipeline products
      • 5.3.7.1. Tempol ( Phase II)
      • 5.3.7.2. AEOL-10150 (Phase I)

6. North America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
  • 6.3.Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Region, 2021-2031, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)

7. UK and European Union Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
  • 7.3.Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Region, 2021-2031, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)

8. Asia Pacific Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
  • 8.3.Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Region, 2021-2031, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)

9. Latin America Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
  • 9.3.Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Region, 2021-2031, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)

10. Middle East and Africa Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
  • 10.3.Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Region, 2021-2031, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Treatment Market: By Treatment, 2021-2031, USD (Million)

11. Company Profile

  • 11.1. Aeolus Pharmaceuticals
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Cantex Pharmaceuticals, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Cleveland BioLabs, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Gamida Cell Ltd.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Nanotherapeutics, Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. NeoStem, Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Onconova Therapeutics, Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Osiris Therapeutics, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Tonix Pharmaceuticals Holding Corp
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Others
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives